TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29898838

Group type: EXPERIMENTAL
Intervention: 1.5 ng IGF1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 15 ng IGF1
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 26924243

Group type: EXPERIMENTAL
Intervention: Camicinal 125 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Camicinal 25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Camicinal 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23801256

Group type: EXPERIMENTAL
Intervention: Aripiprazole (mean dose 5.5 mg/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 1.12 mg/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 59

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 59
Study: 22764184

Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI) measured using a sensitive assay (VITROS Trop I ES, Ortho Clinical Diagnostics)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 808
Study: 20082200

Group type: EXPERIMENTAL
Intervention: Intraoperative orbital floor triamcinolone acetonide (1 ml = 40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4‐week postoperative oral prednisolone
Number of subjects: 40
Study: 19013239

Group type: EXPERIMENTAL
Intervention: 0.3% DHEA cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% DHEA cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% DHEA cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical DHEA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0% DHEA cream)
Number of subjects: 60
Study: 15907404

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg/day, n = 48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 96
Study: 12789465

Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 399

Group type: COMPARATOR
Intervention: RT
Number of subjects: 399
Study: 10721943

Group type: EXPERIMENTAL
Intervention: Total mastectomy with axillary dissection
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Tumours of size 1-9 mm
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Primary adjuvant therapy
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 1053
Study: 8520606

Group type: EXPERIMENTAL
Intervention: IUD insertion by physicians
Number of subjects: 1711

Group type: COMPARATOR
Intervention: IUD insertion by nurses
Number of subjects: 1711

Group type: COMPARATOR
Intervention: IUD insertion by physicians (nulliparous)
Number of subjects: 1711

Group type: COMPARATOR
Intervention: IUD insertion by nurses (nulliparous)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 1711
Study: 2019190

Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional bed treatment (turned every 2 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional bed treatment
Number of subjects: 0
Study: 6290435

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg oral
Number of subjects: 6
Study: 31042143

Group type: EXPERIMENTAL
Intervention: Therapist telephone-delivered CBT (TCBT)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Web-based CBT (WCBT)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 558
Study: 28874171

Group type: EXPERIMENTAL
Intervention: Galium‐Heel® (low‐dose multicomponent medicine) administered twice a day for six non‐consecutive months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Galium‐Heel® (low‐dose multicomponent medicine)
Number of subjects: 80
Study: 25439772

Group type: EXPERIMENTAL
Intervention: Epic bioprosthesis (n=99)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Magna bioprosthesis (n=100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mitroflow bioprosthesis (n=101)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300
Study: 23743472

Group type: EXPERIMENTAL
Intervention: Postoperative gum chewing every 2 hours for 15 minutes
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard postoperative care without gum chewing
Number of subjects: 179
Study: 21371699

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 372

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 372

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 372
Study: 19268614

Group type: EXPERIMENTAL
Intervention: Tailored behavioural treatment protocol (TBT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Exercise based physical therapy protocol (EBT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both TBT and EBT
Number of subjects: 122
Study: 17073988

Group type: EXPERIMENTAL
Intervention: Skin care and makeup instructions from dermatologists
Number of subjects: 50

Group type: COMPARATOR
Intervention: No specific instructions from dermatologists
Number of subjects: 50
Study: 14707796

Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Partner willingness to have HIV‐1 testing
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mixed feeding
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Not breast feeding
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: HIV‐1 infection
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Birth weight <3000 g
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Maternal employment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Paying <$12.5 per month in house rent
Number of subjects: 111
Study: 12234950

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 70
Study: 9885731

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass pollen extract (9,500 BU/ml)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8004299

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (5 mg x 2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intravenous albuterol (0.5 mg)
Number of subjects: 47
Study: 2591460

Group type: EXPERIMENTAL
Intervention: 3 g Heptaminol Adenosine Phosphate (HAP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1242861

Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate (12 metered-doses per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dexamethasone Isonicotinate (12 metered-doses per day)
Number of subjects: 20
Study: 7441333

Group type: EXPERIMENTAL
Intervention: Laminectomy followed by radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 31821452

Group type: EXPERIMENTAL
Intervention: Amoxicillin (7-day therapy)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 31775353

Group type: EXPERIMENTAL
Intervention: Supplement A (50 mg of blackcurrant anthocyanin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Supplement B (50 mg of blackcurrant anthocyanin plus vitamin E)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 24
Study: 28870680

Group type: EXPERIMENTAL
Intervention: MYC gene amplification without polysomy-8
Number of subjects: 1060

Group type: COMPARATOR
Intervention: MYC amplification with polysomy-8, polysomy-8 only, and normal MYC without polysomy-8
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Nuclear Myc protein expression
Number of subjects: 1060
Study: 27509519

Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Australian Guide to Healthy Eating (AGHE)
Number of subjects: 39
Study: 24802722

Group type: EXPERIMENTAL
Intervention: AZD7325 2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AZD7325 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22092918

Group type: EXPERIMENTAL
Intervention: Psoriatic lesions
Number of subjects: 111

Group type: COMPARATOR
Intervention: Contralateral uninvolved sites
Number of subjects: 111
Study: 19403903

Group type: EXPERIMENTAL
Intervention: T12PR12 group (telaprevir, peginterferon alfa‐2a, and ribavirin for 12 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: T12P12 group (telaprevir and peginterferon alfa‐2a without ribavirin for 12 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: T12PR24 group (telaprevir, peginterferon alfa‐2a, and ribavirin for 12 weeks, followed by peginterferon alfa‐2a and ribavirin for 12 more weeks)
Number of subjects: 334

Group type: COMPARATOR
Intervention: PR48 group (control, peginterferon alfa‐2a and ribavirin for 48 weeks)
Number of subjects: 334
Study: 17989272

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan twice a week for 16 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard medical care without exercise rehabilitation
Number of subjects: 52
Study: 14508838

Group type: EXPERIMENTAL
Intervention: Standard fractionated radiation treatment arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperfractionated radiation treatment arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients attending college
Number of subjects: 0

Group type: COMPARATOR
Intervention: All other education levels
Number of subjects: 0
Study: 11199361

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily (QD)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily (BID)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily (QD)
Number of subjects: 310
Study: 9406621

Group type: EXPERIMENTAL
Intervention: Non-linear amplification circuit (K-amp circuit)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Linear hearing aid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Previous aid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of preferences
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Compression amplification circuit
Number of subjects: 45
Study: 1589586

Group type: EXPERIMENTAL
Intervention: Lithium (steady-state serum levels 0.9-1.3 mEq/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3837123

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31888752

Group type: EXPERIMENTAL
Intervention: Intervention arm of the trial
Number of subjects: 1618

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1618
Study: 27760998

Group type: EXPERIMENTAL
Intervention: febuxostat 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: benzbromarone 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: febuxostat 20 mg and benzbromarone 25 mg (feb/ben)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 25645166

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control activity (e.g., reading newspaper)
Number of subjects: 32
Study: 24018253

Group type: EXPERIMENTAL
Intervention: Educational intervention (2 interactive workshops on the prevention of osteoporosis)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (information by post)
Number of subjects: 216
Study: 21336464

Group type: EXPERIMENTAL
Intervention: Written Asthma Action Plans (WAAPs)
Number of subjects: 300
Study: 20142183

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2201

Group type: COMPARATOR
Intervention: MED
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 2201
Study: 18181335

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg every 20 minutes, max 40 mg in the first hour, then 20 mg every 4 hours for up to 72 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous terbutaline (initially infused at 10 microg/min, increased to max 25 microg/min, then switched to subcutaneous injection of 0.25 mg every 4 hours for 24 hours)
Number of subjects: 40
Study: 15152270

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (Mifepristone and Placebo)
Number of subjects: 24
Study: 11282906

Group type: EXPERIMENTAL
Intervention: Shear stress induced flow-dependent vasodilation in NC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Endothelial removal in NC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NO synthase inhibitor Nomega-nitro-L-arginine (L-NNA) in NC
Number of subjects: 32

Group type: COMPARATOR
Intervention: Flow-mediated dilation in HT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Flow-mediated dilation in HChol
Number of subjects: 32
Study: 9001163

Group type: EXPERIMENTAL
Intervention: SR-NaF
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 8096703

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) alone at a maintenance dose of 250 mg every 6 h
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Cotherapy with acyclovir (ACV) at 800 mg every 6 h
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 265
Study: 3560381

Group type: EXPERIMENTAL
Intervention: Group-practice model
Number of subjects: 2299
Study: 31859541

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg (every 4 weeks or 8 weeks; first three doses every 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study: 31704024

Group type: COMPARATOR
Intervention: Control (CON; 0.55 kg DM of a 20% CP and 20% fat MR per day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intermediate (IL; 0.66 kg DM of a 26% CP and 17% fat MR per day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High (HL; 0.77 kg DM of a 26% CP and 17% fat MR per day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aggressive (AL; 0.87 kg DM of a 26% CP and 17% fat MR per day)
Number of subjects: 4
Study: 31300494

Group type: COMPARATOR
Intervention: Oxygen 70 L/min, airway opened by laryngoscopy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen 70 L/min with jaw thrust
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen 10 L/min with jaw thrust
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen 2 L/min with jaw thrust
Number of subjects: 100
Study: 27788026

Group type: EXPERIMENTAL
Intervention: Amitriptyline (1 mg/kg/day)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Topiramate (2 mg/kg/day)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 328
Study: 26327768

Group type: EXPERIMENTAL
Intervention: NAFLD group
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: NAFLD group stratified by BMI < 24 kg/m2
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: NAFLD group stratified by 24 kg/m2 ≤ BMI < 28 kg/m2
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: NAFLD group stratified by BMI ≥ 28 kg/m2
Number of subjects: 4736
Study: 23238577

Group type: EXPERIMENTAL
Intervention: STOP-Bang score ≥ 3 with serum HCO₃⁻ level ≥ 28 mmol/L
Number of subjects: 384

Group type: COMPARATOR
Intervention: STOP-Bang score ≥ 3 without serum HCO₃⁻ level
Number of subjects: 384
Study: 20704458

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium fast-disintegrating tablets (FDTs) 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial tablets of diclofenac potassium 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19801929

Group type: EXPERIMENTAL
Intervention: Probiotic prophylaxis (Ecologic 641)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 17011374

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil (phase 1)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Dose optimization and customized instructions (phase 2)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Phase 2 for initially unsatisfied patients
Number of subjects: 1109
Study: 15001726

Group type: EXPERIMENTAL
Intervention: Interpersonal group therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Group sessions for partners of persons with bipolar disorder
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Patient and family psychoeducation
Number of subjects: 11
Study: 12193264

Group type: EXPERIMENTAL
Intervention: Calcium sulphate grafting
Number of subjects: 20

Group type: COMPARATOR
Intervention: No calcium sulphate grafting (Control)
Number of subjects: 20
Study: 9580524

Group type: EXPERIMENTAL
Intervention: Prednisone 0.5 mg/kg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8114181

Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 87

Group type: COMPARATOR
Intervention: PC
Number of subjects: 87
Study: 3384469

Group type: EXPERIMENTAL
Intervention: High NaCl diet (400 mEq Na, 400 mEq Cl, 100 mEq K)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low NaCl diet (10 mEq Na, 40 mEq Cl, 100 mEq K)
Number of subjects: 22
Study: 31652094

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg orally on days 1 to 21 of a 28-day cycle)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 182

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 182
Study: 29653555

Group type: EXPERIMENTAL
Intervention: Online mindfulness-based program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall recruitment, retention, extent of questionnaire completion, usability and acceptability of, and adherence to the program
Number of subjects: 75
Study: 28225205

Group type: EXPERIMENTAL
Intervention: Oxygen at FiO2 of 0.50
Number of subjects: 11

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 11
Study: 25179315

Group type: EXPERIMENTAL
Intervention: Para-right bundle branch (para-RBB) pacing
Number of subjects: 41

Group type: COMPARATOR
Intervention: Right ventricular apex (RVA) pacing
Number of subjects: 41
Study: 24325111

Group type: EXPERIMENTAL
Intervention: Task-oriented approach in combination with articulation approach
Number of subjects: 44

Group type: COMPARATOR
Intervention: Articulation approach alone
Number of subjects: 44
Study: 22136481

Group type: EXPERIMENTAL
Intervention: 500 μg vitamin B12 and 400 μg folic acid daily (with 15 μg (600 IU) vitamin D included)
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo tablet (with 15 μg (600 IU) vitamin D included)
Number of subjects: 2919
Study: 19501753

Group type: EXPERIMENTAL
Intervention: Low protein drink (13% protein energy/87% carbohydrate energy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Medium protein drink (25% protein energy/75% carbohydrate energy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High protein drink (50% protein energy/50% carbohydrate energy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control drink (low energy, 328 kJ)
Number of subjects: 28
Study: 16958121

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 12755456

Group type: EXPERIMENTAL
Intervention: Venlafaxine (225 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12, 25, or 50 mg)
Number of subjects: 14
Study: 11139672

Group type: EXPERIMENTAL
Intervention: Group 1: General practitioners prescribed hepatitis C virus testing based on identified risk factors.
Number of subjects: 184

Group type: COMPARATOR
Intervention: Group 2: General practitioners used posters and leaflets to assist in screening for hepatitis C virus.
Number of subjects: 184
Study: 9090331

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1996
Study: 2037706

Group type: EXPERIMENTAL
Intervention: AICA-riboside (10, 25, 50, and 100 mg/kg doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AICA-riboside (IV and oral administration)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AICA-riboside (IV administration)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AICA-riboside (oral administration)
Number of subjects: 6
Study: 7264434

Group type: EXPERIMENTAL
Intervention: 170 micrometer standard blood filter
Number of subjects: 155

Group type: COMPARATOR
Intervention: Saline-washed red blood cells
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 20 to 25 micrometer microaggregate blood filters
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 40 micrometer microaggregate screen filter
Number of subjects: 155
Study: 31872901

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 30531489

Group type: EXPERIMENTAL
Intervention: Behavioral modification + exercise from 0 to 3 months (CWT1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensified behavioral modification (iBM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavioral modification + exercise from 6 to 9 months (CWT2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 120
Study: 29212546

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Systems (CDSS) with evidence-based order sets
Number of subjects: 0
Study: 25818798

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 50

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 50